Biogen and Alectos Therapeutics Announce License and Collaboration Agreement for AL01811, a Novel GBA2 Inhibitor for the Potential Treatment of Parkinson’s Disease
06 Junho 2022 - 8:30AM
Biogen Inc. (Nasdaq: BIIB) -- Biogen and Alectos Therapeutics have
entered into a license and collaboration agreement to develop and
commercialize a novel preclinical selective GBA2 inhibitor,
AL01811, which has first-in-class potential as an oral disease
modifying treatment for patients with Parkinson’s disease (PD).
This collaboration combines Alectos’ expertise in small-molecule
therapeutics with Biogen’s development capabilities in movement
disorders.
Increasing evidence suggests that lysosomal dysfunction plays a
key role in the pathology of neurodegenerative disease, including
PD. Small-molecule GBA2 inhibitors have been shown to reduce
lysosomal pH and increase levels of the lysosomal proton pump
vATPase, which is involved in maintaining the acidic pH required
for lysosomal function. Currently, there are no approved disease
modifying therapies for PD, creating significant unmet needs for
patients seeking to slow disease progression. If approved, AL01811
has the potential to improve the standard of care for movement
disorders such as PD, which affects approximately 10 million
patients worldwide1.
“Through this collaboration with Alectos, we hope to improve the
lives of people living with Parkinson’s disease by advancing the
research and development of a potential-first-in-class oral
treatment that may slow disease progression,” said Priya Singhal,
Interim Head of R&D at Biogen. “At Biogen, we aim to advance
therapies that serve people with movement disorders, enabling them
to have greater independence and quality of life.”
“By combining Alectos’ expertise in small-molecule therapeutics
with Biogen’s global development expertise in Parkinson’s disease,
we believe we will be well-positioned to help bring AL01811 to
patients in need,” said Ernest McEachern, Ph.D., President and CEO
at Alectos Therapeutics. “We’re also energized by the opportunity
to tap into Biogen’s commercial acumen in order to advance the
standard of care in Parkinson’s disease and movement disorders more
broadly.”
Under the terms of the agreement, Biogen will make an upfront
payment of $15 million to Alectos Therapeutics for an exclusive
global license to AL01811 and additional unnamed backup molecules.
In addition, Alectos is eligible to receive up to $77.5M in
potential development payments and $630M in potential commercial
payments should the collaboration achieve certain milestones.
Alectos is also eligible to receive tiered royalties in the
high-single-digits to mid-teens. Moving forward, both companies
will collaborate on preclinical activities for AL01811 and, once
AL01811 is advanced to the clinic, Biogen will assume sole
responsibility for all development, regulatory, manufacturing, and
commercial activities and costs.
About BiogenAs pioneers in neuroscience, Biogen
discovers, develops, and delivers worldwide innovative therapies
for people living with serious neurological diseases as well as
related therapeutic adjacencies. One of the world’s first global
biotechnology companies, Biogen was founded in 1978 by Charles
Weissmann, Heinz Schaller, Sir Kenneth Murray, and Nobel Prize
winners Walter Gilbert and Phillip Sharp. Today, Biogen has a
leading portfolio of medicines to treat multiple sclerosis, has
introduced the first approved treatment for spinal muscular
atrophy, and is providing the first and only approved treatment to
address a defining pathology of Alzheimer’s disease. Biogen is also
commercializing biosimilars and focusing on advancing the
industry’s most diversified pipeline in neuroscience that will
transform the standard of care for patients in several areas of
high unmet need.
In 2020, Biogen launched a bold 20-year, $250 million initiative
to address the deeply interrelated issues of climate, health, and
equity. Healthy Climate, Healthy Lives™ aims to eliminate fossil
fuels across the company’s operations, build collaborations with
renowned institutions to advance the science to improve human
health outcomes, and support underserved communities.
The company routinely posts information that may be important to
investors on its website at www.biogen.com. To learn more,
please visit www.biogen.com and follow Biogen on social
media
– Twitter, LinkedIn, Facebook, YouTube.
About Alectos TherapeuticsAlectos Therapeutics
is a leader in the discovery and preclinical development of novel
small-molecule therapeutics to treat neurological diseases. Alectos
focuses on identifying and developing innovative disease modifying
strategies to address complex neurological conditions for which
there are no effective treatments, including Alzheimer’s disease
and Parkinson’s disease. For more information, please visit
www.alectos.com and follow Alectos on social media – Twitter,
LinkedIn.
Biogen Safe Harbor This news release
contains forward-looking statements, including statements made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995, the potential benefits of AL01811;
the potential benefits and results that may be achieved through our
collaboration with Alectos Therapeutics; the potential benefits,
safety and efficacy of AL01811; the potential treatment of
neurological and neurodegenerative diseases; the potential of our
commercial business and pipeline programs; and our strategy and
plans. These statements may be identified by words such as “aim,”
“anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,”
“goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will,”
“would” and other words and terms of similar meaning. You should
not place undue reliance on these statements, or the scientific
data presented.
These statements involve risks and uncertainties that could
cause actual results to differ materially from those reflected in
such statements, including without limitation, the risks of
unexpected costs or delays; the risk of other unexpected hurdles;
failure to protect and enforce our data, intellectual property and
other proprietary rights and uncertainties relating to intellectual
property claims and challenges; regulatory authorities may require
additional information or further studies; third party
collaboration risks; and the direct and indirect impacts of the
ongoing COVID-19 pandemic on our business, results of operations
and financial condition. The foregoing sets forth many, but not
all, of the factors that could cause actual results to differ from
our expectations in any forward-looking statement. Investors should
consider this cautionary statement as well as the risk factors
identified in our most recent annual or quarterly report and in
other reports we have filed with the U.S. Securities and Exchange
Commission. These statements are based on our current beliefs and
expectations and speak only as of the date of this news release. We
do not undertake any obligation to publicly update any
forward-looking statements, whether as a result of new information,
future developments or otherwise.
References:
- Statistics, Parkinson’s Foundation.
https://www.parkinson.org/Understanding-Parkinsons/Statistics
|
|
MEDIA CONTACT:BiogenAshleigh Koss+ 1 908 205
2572public.affairs@biogen.com |
INVESTOR CONTACT:BiogenMike Hencke+1 781 464
2442IR@biogen.com |
|
|
Alectos
TherapeuticsErnest McEachern+ 1 604 628
7129info@alectos.com |
|
Biogen (NASDAQ:BIIB)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Biogen (NASDAQ:BIIB)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024